

New England Biolabs Certificate of Analysis

Product Name: ScrFI
Catalog #: R0110S/L
Concentration: 5,000 units/ml
Unit Definition: One unit is defined as the amount of enzyme required to digest 1 µg of Lambda DNA in 1 hour at 37°C in a total reaction volume of 50 µl.
Lot #: 0111407
Assay Date: 07/2014
Expiration Date: 7/2016
Storage Temp: -20 °C
Storage Conditions: 250 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM DTT, 0.1 mM EDTA, 50% Glycerol, 0.15% Triton X-100, 200 µg/ml BSA
Specification Version: PS-R0110S/L v1.0
Effective Date: 25 Jul 2014

Assay Name/Specification (minimum release criteria)	Lot #0111407
Exonuclease Activity (Radioactivity Release) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of a mixture of single and double-stranded [³ H] <i>E. coli</i> DNA and a minimum of 15 units of ScrFI incubated for 4 hours at 37°C releases <0.1% of the total radioactivity.	Pass
Ligation and Recutting (Terminal Integrity) - After a 2-fold over-digestion of Lambda DNA with ScrFI, <5% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with ScrFI.	Pass
Non-Specific DNase Activity (16 hour) - A 50 µl reaction in CutSmart™ Buffer containing 1 µg of Lambda DNA and a minimum of 5 Units of ScrFI incubated for 16 hours at 37°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis. NOTE: although no nuclease degradation is detected under these conditions, extended incubations and/or high concentrations of this enzyme may result in star activity. See the product FAQ for recommended reaction conditions for this enzyme.	Pass
Protein Purity Assay (SDS-PAGE) - ScrFI is >95% pure as determined by SDS PAGE analysis using Coomassie Blue detection.	Pass

* The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.

M. W. Southworth

Kerri Sakowski

Authorized by
Maurice Southworth
25 Jul 2014

Inspected by
Kerri Sakowski
25 Jul 2014

